PMID- 38178769 OWN - NLM STAT- MEDLINE DCOM- 20240108 LR - 20240108 IS - 0376-2491 (Print) IS - 0376-2491 (Linking) VI - 104 IP - 1 DP - 2024 Jan 2 TI - [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients]. PG - 57-62 LID - 10.3760/cma.j.cn112137-20230713-00005 [doi] AB - Objective: To investigate the clinical and prognostic characteristics of newly diagnosed multiple myeloma (NDMM) patients with myelofibrosis (MF). Methods: The clinical data of 160 NDMM patients admitted to Henan Provincial People's Hospital from January 2012 to July 2022 were analyzed retrospectively. They were divided into MF group(n=74) and non-MF group(n=86) according to whether combined with MF. Patients in MF group were further splited into MF-1 group (n=47) and MF-2/3 group (n=27). All patients were treated with bortezomib and immunomodulatory-based combination therapy. The efficacy was evaluated after 4 courses, and the clinical features and prognosis between the two groups were compared. The deadline for follow-up was December 30, 2022 and the median follow-up period [M (Q(1), Q(3))] was 23.5 (14.4, 40.5) months. Kaplan-Meier method was used for survival analysis, and Cox regression model was used to analyze the influencing factors of survival. Results: Among 160 patients with NDMM, 91 were males and 69 were females, with a median age [M (Q(1), Q(3))] of 59 (54, 69) years. In MF group, the bone marrow immature plasma cell percentage, total plasma cell percentage were 9.6% (3.2%, 28.5%) and 36.4% (18.5%, 51.1%), respectively, which were higher than 6.0% (1.2%, 17.2%) and 24.0% (12.0%, 46.0%) of the non-MF group (both P<0.05). Hb level was 84.0(74.5, 100.5)g/L and PLT was (151.99+/-90.68) x10(9)/L in the MF group, which were lower than 96.0 (81.0, 112.0)g/L and (180.38+/-85.32) x10(9)/L of non-MF group (both P<0.05). But there were no significant differences in ISS stage, karyotypic and fluorescence in situ hybridization (FISH) high-risk genetic abnormalities between the two groups (all P>0.05). Objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) were not significantly different between the two groups (all P>0.05). The rate of 17p- was 25.9% (7/27) in MF-2/3 group, which was higher than 8.1% (7/86) of non-MF group (P=0.049). The median OS of the MF-2/3 group was 25.0 (95%CI: 23.6-26.4) months, which was shorter than that of the non-MF group (54.0 months, P=0.031). Multivariate Cox regression analysis showed that grade MF-2/3 was not a risk factor for OS in NDMM patients (HR=1.507, 95%CI: 0.624-3.993, P=0.425). Conclusions: The ratio of bone marrow immature plasma cells and total plasma cells in NDMM patients with MF are higher than that in patients without MF, and the Hb and PLT are lower than that in patients without MF. NDMM patients with grade 2/3 MF have shorter survival than those without MF. FAU - Zhang, L AU - Zhang L AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Li, Y L AU - Li YL AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Liu, Y M AU - Liu YM AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Liu, Y B AU - Liu YB AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Shang, B J AU - Shang BJ AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Cheng, W AU - Cheng W AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Dong, X Y AU - Dong XY AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. FAU - Zhu, Z M AU - Zhu ZM AD - Hematological Institute of Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Hematopathology, CAR-T Cell Therapy and Transformation Engineering Research Center of Henan Province, People's Hospital of Zhengzhou University, Zhengzhou 450003, China. LA - chi GR - LHGJ20220011/Henan Province Medical Science and Technology Research Project/ GR - Wjlx2022014/Henan Medical Education Research Project/ PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Yi Xue Za Zhi JT - Zhonghua yi xue za zhi JID - 7511141 SB - IM MH - Male MH - Female MH - Humans MH - Prognosis MH - *Multiple Myeloma/diagnosis MH - In Situ Hybridization, Fluorescence MH - *Primary Myelofibrosis MH - Retrospective Studies EDAT- 2024/01/05 06:43 MHDA- 2024/01/08 06:43 CRDT- 2024/01/05 03:15 PHST- 2024/01/08 06:43 [medline] PHST- 2024/01/05 06:43 [pubmed] PHST- 2024/01/05 03:15 [entrez] AID - 10.3760/cma.j.cn112137-20230713-00005 [doi] PST - ppublish SO - Zhonghua Yi Xue Za Zhi. 2024 Jan 2;104(1):57-62. doi: 10.3760/cma.j.cn112137-20230713-00005.